Your browser doesn't support javascript.
loading
A Novel Variant in the LIPA Gene Associated with Distinct Phenotype.
Sarajlija, A; Armengol, L; Maver, A; Kitic, I; Prokic, D; Cehic, M; Djuricic, M S; Peterlin, B.
Afiliación
  • Sarajlija A; Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Pediatric Day Care Hospital, Belgrade, Serbia.
  • Armengol L; School of Medicine, University of Belgrade, Belgrade, Serbia.
  • Maver A; Quantitative Genomic Medicine Laboratories (qGenomics), Esplugues del Llobregat, Spain.
  • Kitic I; Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Prokic D; Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Department of Gastroenterology and Hepatology, Belgrade, Serbia.
  • Cehic M; School of Medicine, University of Belgrade, Belgrade, Serbia.
  • Djuricic MS; Mother and Child Health Care Institute of Serbia "Dr. Vukan Cupic", Department of Gastroenterology and Hepatology, Belgrade, Serbia.
  • Peterlin B; School of Medicine, University of Belgrade, Belgrade, Serbia.
Balkan J Med Genet ; 25(1): 93-100, 2022 Jun.
Article en En | MEDLINE | ID: mdl-36880034
Deficiency of lysosomal acid lipase (LAL-D) is caused by biallelic pathogenic variants in the LIPA gene. Spectrum of LAL-D ranges from early onset of hepatosplenomegaly and psychomotor regression (Wolman disease) to a more chronic course (cholesteryl ester storage disease - CESD). The diagnosis is based on lipid and biomarker profiles, specific liver histopathology, enzyme deficiency, and identification of causative genetic variants. Biomarker findings are a useful for diagnostics of LAL-D, including high plasma concentration of chitotriosidase as well as elevated oxysterols. Current treatment options include enzyme replacement therapy (sebelipase-alpha), statins, liver transplantation, and stem cell transplantation. We present two pairs of siblings from Serbia with a distinctive phenotype resembling LAL-D with a novel variant of unknown significance (VUS) detected in the LIPA gene and residual LAL activity. All patients presented with hepatosplenomegaly at early childhood. In siblings from family 1, compound heterozygosity for a pathogenic c.419G>A (p.Trp140Ter) variant and a novel VUS c.851C>T (p.Ser284Phe) was detected. Patients from family 2 were homozygous for c.851C>T VUS and both have typical histopathologic findings for LAL-D in the liver. Enzyme activity of LAL was tested in three patients and reported as sufficient, and therefore enzyme replacement therapy could not be approved. When confronted with a challenge of diagnosing an inherited metabolic disorder, several aspects are taken into consideration: clinical manifestations, specific biomarkers, enzyme assay results, and molecular genetic findings. This report brings cases to light which have a considerable discrepancy between those aspects, namely the preserved LAL enzyme activity in presence of clinical manifestations and rare variants in the LIPA gene.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Balkan J Med Genet Año: 2022 Tipo del documento: Article Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Balkan J Med Genet Año: 2022 Tipo del documento: Article Pais de publicación: Polonia